

Equity	% Chg			
	10-Sept	1-day	1-mth	3-mth
India				
Sensex	15,597	0.0	4.9	10.7
Nifty	4,508	(0.0)	4.0	8.7
Global/Regional markets				
Dow Jones	13,128	0.1	(0.8)	(2.2)
Nasdaq	2,559	(0.3)	0.6	(0.5)
FTSE	6,134	(0.9)	1.6	(6.6)
Nikkei	15,804	0.3	(5.7)	(11.4)
Hang Seng	24,109	0.5	10.6	16.9

Value traded (Rs bn)	BSE	NSE
Cash	40.5	88.8
Derivatives	10.1	373.3
Total	50.6	462.1

Net inflows	Recent trends (days)			
	(Rs bn)	7-Sept	-7d	-15d
FII	5.8	27.9	43.2	(56.9)
MF	(1.9)	13.6	27.3	53.8

Forex / Crude	% Chg			
	10-Sept	1day	1mth	3mth
Rs/US\$	40.6	0.0	(0.2)	0.4
Euro/US\$	1.4	(0.1)	1.3	3.2
Crude(\$/bbl)	77.9	0.5	9.0	18.0

Mkt movers (Rs)	Close	Pr. Cl.	% Chg
Top gainers			
TVS Motor Co	72.7	64.3	13.0
Taneja Aerospace	184.9	168.1	10.0
Marksans Pharma	61.2	55.7	10.0
Top losers			
Gammon India	420.7	461.1	(8.8)
Transworld Info	91.8	99.5	(7.8)
HCL-Infosystems	215.3	229.3	(6.1)

In focus

Cadila Healthcare – Company Update

Steady growth; Pantoprazole verdict may upset estimates **CMP: Rs 320 Target: Rs 416 BUY**

HDIL – Initiating Coverage

Strong underpinnings **CMP: Rs 533 Target: Rs 694 BUY**

Today's top picks

IFCI, HDIL, NTPC, REL, SBI.

News track

- ❖ Bharti Airtel has received a Facilities-Based Operator (FBO) licence in Singapore that permits the company to offer global voice and data services in that country. The licence was awarded to the company's subsidiary Bharti Airtel (Singapore).(BS)
- ❖ Reliance Communications (RCom) has received approvals from Maharashtra and Maharashtra Industrial Development Corporation (MIDC) for its proposed 45-acre special economic zone (SEZ). The SEZ would cater to the emerging information technology (IT) and information technology-enabled services (ITeS) sectors.(BS)
- ❖ Idea Cellular has decided to demerge the passive infrastructure of the company into a wholly owned subsidiary.(BL)
- ❖ Bajaj Auto Ltd on Monday denied that the Akurdi plant near Pune has been shut down, even as workers claim that production of two-wheelers has been totally discontinued from September 1 and that the assembly lines are idle. (Hindu)
- ❖ Madhucon Projects has bagged the Rs 812mn road improvement works by Pimpri-Chinchwad Navnagar Development, Pune. The work is to be completed in two years. (BL)
- ❖ 15 coal blocks will be awarded to the power sector at a meeting of the coal ministry's screening committee on Thursday. These blocks have reserves of around 3.6bn tones capable of generating 18,000MW of power. (Mint)
- ❖ Ranbaxy looking for partners to fund R&D, may finalize a model by end 2007 (ET)
- ❖ Sun Pharma has been sued by US based Sepracor for patent infringement for anti-allergy drug desloratidine branded as Clarinex (ET)

Source: BL: Business Line, BS: Business Standard, ET: Economic Times, FE: Financial Express

Volume shockers

(No of shares)	10-Sept	2-mth avg	Chg (x)
Ruchi Soya Indu	323,483	21,326	15.2
Gammon India	837,896	60,762	13.8
Marksans Pharma	1,501,579	110,399	13.6

Delivery toppers

	Del (%)	Total vol	Cons days up
HDFC Bank	64.4	426,883	3
Eveready Industries	53.6	447,519	5
Chennai Petroleum	53.4	657,010	3

Cadila Healthcare

Company Update

CMP: Rs 320

Target: Rs 416

BUY

Alok Dalal

(91-22) 6612 4750

alok.dalal@religare.in

BSE code	532321
NSE code	CADILAHC


Company data

Particulars	
Market cap (Rs bn / US\$ mn)	40.5/992
Outstanding equity shares (mn)	125.6
52-week high/low (Rs)	414/273
6-month average daily volume	16,340

Financial snapshot

Particulars	FY07	FY08E	FY09E
Sales (Rs mn)	18,288.0	23,238.5	27,023.1
Growth (%)	23.2	27.1	16.3
Adj net profit (Rs mn)	2,338.0	2,902.6	3,408.7
Growth (%)	53.4	24.1	17.4
FDEPS (Rs)	18.6	23.1	27.1
Growth (%)	53.4	24.1	17.4
P/E (x)	17.2	13.8	11.8
RoE (%)	29.9	29.9	28.3

Risk-return profile



Shareholding pattern

(%)	Jun-07	Mar-07
Promoters	72.0	72.0
FIs	4.8	5.0
Banks & FIs	15.1	14.5
Public	8.1	8.5

Stock performance

Returns (%)	CMP	1-mth	3-mth	6-mth
Cadila Healthcare	320	(12.8)	(5.0)	1.7
Sensex	15,597	4.9	10.7	21.0
BSE HC	3,721	3.3	(0.8)	1.3

Company website www.zyduscadila.com

Steady growth; Pantoprazole verdict may upset FY09 estimates

Our interaction with the management of Cadila Healthcare (CHL) suggests that both its domestic and international operations are on track to deliver a robust performance over the next two years. While domestic market operations are likely to be ahead of the industry, export sales would be driven by the US, French and Brazilian markets. Zydus France is on track to turnaround in FY08 and will have a positive impact on margins. The company's JV with Hospira for oncology products is also progressing smoothly. Further, CHL is eyeing acquisitions in the European markets purely with a view to getting an entry point into the region, while using France as a base for the entire market.

We believe CHL's growth drivers remain strong and estimate that the company will witness an earnings CAGR of 20.7% to Rs 3.4bn over FY07-FY09. We maintain a Buy on the stock with a target price of Rs 416. A key concern for the medium-term is the ongoing patent litigation on Altana's Pantoprazole (now part of Nycomed) which is now proceeding to the trial stage. While the court has stated that the generic companies (Teva and Sun Pharma) would need to meet a higher burden of proof, if the trial goes in their favour and a generic version is launched in FY09, it could significantly affect our FY09 estimates for CHL.

Key takeaways

Eyeing acquisitions in Europe

CHL is eyeing acquisitions in the generic space in European markets like Spain and Italy. The company is looking at acquiring small pharmaceutical companies in this region purely to get an entry into this market. It intends to use France as its base, where it is already established through its subsidiary Zydus France, and penetrate the rest of the market. The management may fund the acquisition from internal accruals and debt rather than raise money through an FCCB issue.

Nikkho to grow at 20-25% annually over the next two years

CHL's latest acquisition in Brazil, Nikkho (acquired for US\$ 26mn), is expected to grow at 20-25% annually over the next two years. The growth would be driven by new product introductions in the Brazilian market, which is very similar to the domestic market. The company is looking at merging CHL's existing operations and Nikkho's operations under one umbrella. This will help its Brazilian business to turnaround in FY09. Nikkho has 22 products in the Brazilian market.

Domestic market expected to grow above industry average

CHL has a strong presence in the domestic market and is expected to grow above the industry average over the next two years. Growth would be driven by branded formulations, both from new product introductions and its existing basket of products. The other growth drivers would be the consumer division and Carnation Nutra Analogue Foods, the manufacturers of Nutralite.

French subsidiary on track to turnaround in FY08

The management reiterated that Zydus France is on track to turnaround in FY08. The subsidiary posted an operating profit for the first time ever in Q1FY08 and is expected to maintain this performance throughout the year. The company will launch five to six products in the French market by December 2007. In addition, it has received 17 cumulative site approvals from the French regulatory authority.

Filed its fifth IND 'ZYH7' for treating dyslipidemia and metabolic disorders

CHL recently filed its fifth IND, ZYH7, a novel candidate for treating dyslipidemia and metabolic disorders. CHL has four INDs in various stages of clinical trials starting with ZYH1 for treating dyslipidemia and ZYI1 for treating pain and inflammation which are undergoing phase-II trials. ZYH2 for treating diabetes and the novel CB-1 antagonist, ZY01, for treating obesity are undergoing phase-I trials.

Pantoprazole litigation trial to begin shortly, crucial for CHL's FY09 operations

Protonix (Pantoprazole Sodium) is an anti-ulcer drug belonging to Altana, the patent on which expires on July 19, 2010. Protonix is sold in the US by Altana's licensing partner Wyeth Pharma, who is facing a Para IV challenge by Teva Pharma and Sun Pharma. Altana was subsequently acquired by Nycomed earlier this year.

Nycomed and Wyeth Pharma had earlier filed for a preliminary injunction against Teva and Sun to prevent a potential launch of a generic version of Protonix. The US District Court in its hearing on September 7 determined that Teva had raised sufficient questions about the patent's validity to preclude issuance of a preliminary injunction. However, the Court did not conclude that the patent was invalid and emphasised that its findings were preliminary. **The case will now proceed to trial, and the Court has stated that the generic companies would need to meet a higher burden of proof with clear and convincing evidence to support their case.**

Teva has indicated that it is undertaking a thorough analysis of the court's decision before deciding upon the next course of action. The 180-day exclusivity will begin from the date of first commercial marketing or a final court decision. Sun Pharma has recently received the FDA approval and is evaluating launch options.

While we do not foresee any impact on our FY08 estimates from the trial verdict for the Altana JV, our FY09 estimates (revenue of Rs 640mn and PAT of Rs 400mn) could come under pressure if Teva and Sun launch the generic version somewhere in FY09.

Quarterly results

(Rs mn)	Q1FY08	Q1FY07	% Chg YoY	Q4FY07	% Chg QoQ
Net Sales	5,609	4,361	28.6	4,211	33.2
Oth Opr Inc	113	97	16.5	146	(22.6)
Expenditure	(4,610)	(3,560)	29.5	(3,646)	26.4
Operating profit	1,112	898	23.8	711	56.4
Other income	3	49	(93.9)	15	(80.0)
Interest	18	(69)	-	(52)	-
Depreciation	(239)	(197)	21.3	(200)	19.5
PBT	894	681	31.3	474	88.6
Tax	(121)	(76)	59.2	(50)	142.0
APAT	739	584	26.5	389	90.0
OPM (%)	19.4	20.6	(1.2)	16.3	19.1
EPS (Rs)	5.9	4.6	26.5	3.1	90.0

Source: Company, Religare Research

Protonix accounts for 21% of CHL's profitability, making the trial verdict a crucial one for FY09 operations

Valuation


We believe CHL's growth drivers remain strong and estimate that the company will witness an earnings CAGR of 20.7% to Rs 3.4bn over FY07-FY09. We maintain a Buy on the stock with a target price of Rs 416. A key concern for the medium-term is the ongoing patent litigation on Altana's Pantoprazole which is now proceeding to the trial stage. While the court has stated that the generic companies (Teva and Sun Pharma) would need to meet a higher burden of proof, if the trial goes in their favour and a generic version is launched in FY09, it could significantly affect our FY09 estimates for CHL.

Recommendation history

Date	Event	Reco price	Tgt price	Reco
03-May-07	Initiating Coverage	322	416	Buy
01-Aug-07	Results Update	351	416	Buy
11-Sep-07	Company Update	320	416	Buy

Source: Religare Research

Stock performance



Source: Religare Research

Consolidated Financials

Profit and Loss statement

(Rs mn)	FY06	FY07	FY08E	FY09E
Revenues	14,845.0	18,288.0	23,238.5	27,023.1
Growth (%)	18.6	23.2	27.1	16.3
EBITDA	2,877.0	3,521.0	4,717.4	5,674.9
Growth (%)	32.9	22.4	34.0	20.3
Depreciation	779.0	823.0	994.5	1,105.5
EBIT	2,098.0	2,698.0	3,722.9	4,569.4
Growth (%)	45.0	28.6	38.0	22.7
Interest	223.0	301.7	373.2	292.0
Other income	36.0	264.0	46.5	54.0
EBT	1,911.0	2,660.3	3,396.2	4,331.4
Growth (%)	56.0	39.2	27.7	27.5
Tax	243.0	324.0	520.2	637.5
Effective tax rate	12.7	12.2	15.3	14.7
Adj net income	1,524.0	2,338.0	2,902.6	3,408.7
Growth (%)	60.4	53.4	24.1	17.4
Shares outstanding (mn)	125.6	125.6	125.6	125.6
FDEPS (Rs)	12.1	18.6	23.1	27.1
DPS (Rs)	3.8	5.3	6.2	7.2
CEPS (Rs)	18.3	25.2	31.0	35.9

Source: Company, Religare Research

Cash flow statement

(Rs mn)	FY06	FY07	FY08E	FY09E
Net income	1,524.0	2,338.0	2,902.6	3,408.7
Depreciation	779.0	823.0	994.5	1,105.5
Other adjustments	94.0	175.0	65.0	395.3
Changes in WC	(666.0)	222.0	(2,037.1)	494.4
Operating cash flow	1,731.0	3,558.0	1,925.0	5,403.9
Capital expenditure	(1,202.0)	(2,277.0)	(1,410.2)	(1,275.0)
Investments	(247.0)	453.0	-	-
Other investing inc/(exp)	(586.0)	(613.0)	(773.5)	(808.7)
Investing cash flow	(2,035.0)	(2,437.0)	(2,183.7)	(2,083.7)
Free cash flow	(304.0)	1,121.0	(258.7)	3,320.2
Issue of equity	-	314.0	-	-
Issue/repay debt	598.0	103.0	1,900.0	700.0
Dividends paid	(483.0)	(664.0)	(782.7)	(906.3)
Others	14.0	(322.0)	-	-
Financing cash flow	129.0	(569.0)	1,117.3	(206.3)
Beg. cash & cash eq	613.0	438.0	990.0	1,848.5
Chg in cash & cash eq	(175.0)	552.0	858.5	3,113.9
Closing cash & cash eq	438.0	990.0	1,848.5	4,962.4

Source: Company, Religare Research

Balance sheet

(Rs mn)	FY06	FY07	FY08E	FY09E
Cash and cash eq	438.0	990.0	1,848.5	4,962.4
Accounts receivable	1,990.0	2,784.0	3,454.0	3,887.3
Inventories	2,475.0	3,896.0	4,676.6	5,390.4
Others current assets	1,588.0	2,201.0	2,974.5	3,783.2
Current assets	6,491.0	9,871.0	12,953.6	18,023.3
LT investments	714.0	261.0	261.0	261.0
Net fixed assets	7,693.0	8,559.0	9,396.7	9,917.2
CWIP	636.0	1,224.0	802.0	451.0
Total assets	15,534.0	19,915.0	23,413.3	28,652.5
Payables	2,404.0	4,588.0	3,847.2	5,354.7
Others	605.0	858.0	1,012.2	1,146.3
Current liabilities	3,009.0	5,446.0	4,859.5	6,501.0
LT debt	4,432.0	4,535.0	6,435.0	7,135.0
Other liabilities	1,104.0	1,279.0	1,344.0	1,739.3
Equity capital	314.0	628.0	628.0	628.0
Reserves	6,675.0	8,027.0	10,146.8	12,649.2
Net Worth	6,989.0	8,655.0	10,774.8	13,277.2
Total liabilities	15,534.0	19,915.0	23,413.3	28,652.5
BVPS (Rs)	111.3	68.9	85.8	105.7

Source: Company, Religare Research

Financial ratios

	FY06	FY07	FY08E	FY09E
EBITDA margin (%)	19.4	19.3	20.3	21.0
EBIT margin (%)	14.1	14.8	16.0	16.9
Net profit margin (%)	10.3	12.8	12.5	12.6
FDEPS growth (%)	60.4	53.4	24.1	17.4
Receivables (days)	39.6	47.6	49.0	49.6
Inventory (days)	107.5	127.1	136.0	139.0
Payables (days)	102.2	139.4	133.8	127.1
Current ratio (x)	2.2	1.8	2.7	2.8
Interest coverage (x)	9.4	8.9	10.0	15.6
Debt/equity ratio (x)	0.6	0.5	0.6	0.5
ROE (%)	23.6	29.9	29.9	28.3
ROCE (%)	18.0	20.0	22.5	22.5
ROAE (%)	14.5	15.2	17.2	17.6
EV/Sales (x)	3.0	2.4	1.9	1.6
EV/EBITDA (x)	15.4	12.5	9.4	7.8
P/E (x)	26.4	17.2	13.8	11.8
P/BV (x)	3.4	2.9	4.6	3.7
P/CEPS (x)	17.5	12.7	10.3	8.9

Source: Company, Religare Research

HDIL

Initiating Coverage

CMP: Rs 533

Target: Rs 694

BUY

Suman Memani

(91-22) 6612 4736

suman.memani@religare.in

BSE code	532873
NSE code	HDIL


Company data

Particulars	
Market cap (Rs bn / US\$ bn)	115.6/2.9
Outstanding equity shares (mn)	214.4
52-week high/low (Rs)	634/477
Monthly average daily volume	929,170

Financial snapshot

Particulars	FY07	FY08E	FY09E
Sales (Rs mn)	12,034.5	20,780.0	37,160.0
Growth (%)	185.1	72.7	78.8
Adj net profit (Rs mn)	5,418.1	8,615.1	15,572.7
Growth (%)	375.6	59.0	80.8
FDEPS (Rs)	30.1	40.2	72.7
Growth (%)	375.6	33.6	80.8
P/E (x)	17.7	13.3	7.3
RoE (%)	74.5	26.5	32.8

Risk-return profile



Shareholding pattern

(%)	July-07
Promoters	60.6
FIs	6.7
Banks & FIs	21
Public	11.7

Stock performance

Returns (%)	CMP	1-mth	3-mth	6-mth
HDIL	533	2.4	NA	NA
Sensex	15,590	4.9	10.9	21.0

Company website www.hdil.in

Strong underpinnings

Largest land bank in Mumbai; Best play on city's slum rehabilitation scheme

Investment rationale

- ❖ Mumbai-based real estate developer belonging to the Wadhawan Group, with a diversified presence in the residential, commercial, retail and slum rehabilitation segments. Established brand equity, especially in the residential and commercial segments.
- ❖ Highest saleable land bank among listed Mumbai realty players, at 115.8mn sq ft, expected to be executed by 2012. Has completed 24 projects to date totalling ~11.3mn sq ft.
- ❖ Government thrust towards transforming Mumbai into an international financial hub will throw open large opportunities for realty players – HDIL would be the biggest beneficiary considering its dominant position in the city.
- ❖ HDIL is a prominent player in the Maharashtra government's slum rehabilitation scheme (SRS), with 2mn sq ft of land developed under the SRS. Land bank at Mumbai's prime Bandra-Kurla Complex together with prospects for slum rehabilitation for the Mumbai airport and Dharavi projects could generate more value than the company's present market cap.
- ❖ In-principle government approval received for one SEZ. Once notified, this zone will yield a significant valuation upside.

Key concerns


- ❖ Proposed development of 115.8mn sq ft of land in the next five to six years indicates the need for a significant scale-up of execution capability. Any delay in execution is likely to impact the company's financials.
- ❖ Concentration of land reserve in and around Mumbai (85% of total) leaves HDIL vulnerable to any slowdown in realty offtake or prices in the city.

Valuation

- ❖ Initiate Buy with a target price of Rs 694, which is 1x NAV and inversely, a P/E of 7.3x on FY09E EPS of Rs 72.7.


Refer to our report dated 10 September 2007 for further details.

P/E multiple (x)



Source: Religare Research

Market cap/Sales multiple (x)



Source: Religare Resea

Financials

Profit and Loss statement

(Rs mn)	FY06	FY07	FY08E	FY09E
Revenues	4,221.5	12,034.5	20,780.0	37,160.0
Growth (%)	550.1	185.1	72.7	78.8
EBITDA	1,219.4	6,487.5	12,032.2	21,395.1
Growth (%)	406.4	432.0	85.5	77.8
Depreciation & Amortisation	2.6	6.3	12.0	15.0
EBIT	1,216.8	6,481.3	12,020.2	21,380.1
Growth (%)		432.6	85.5	77.9
Interest	105.7	430.0	650.0	1,000.0
Other income	180.2	130.6	130.0	130.0
EBT	1,291.3	6,181.9	11,500.2	20,510.1
Growth (%)	645.6	378.7	86.0	78.3
Tax	152.0	763.7	2,885.0	4,937.4
Effective tax rate (%)	11.8	12.4	25.1	24.1
Net income (adjusted)	1,139.3	5,418.1	8,615.1	15,572.7
Growth (%)	682.1	375.6	59.0	80.8
Shares outstanding(mn)	500.0	1,800.0	2,144.5	2,144.5
FDEPS (Rs)	6.3	30.1	40.2	72.7
DPS (Rs)	-	-	2.0	2.0
CEPS(Rs)	22.8	30.1	40.2	72.7

Source: Company, Religare Research

Cash flow statement

(Rs mn)	FY06	FY07	FY08E	FY09E
Net income (E BT)	1,291.3	6,181.9	11,500.2	20,510.1
Depreciation	4.1	6.3	12.0	15.0
Other non-cash adjustments	(85.8)	237.4	519.2	(1,871.3)
Changes in working capital		(7,426.0)	(29,402.5)	(19,134.7)
Operating cash flow	(72.9)	(1,000.4)	(17,371.2)	(481.0)
Capital expenditure	(19.2)	(189.5)	(60.5)	(54.0)
Investments	(532.1)	(517.6)	(2,449.6)	(554.0)
Other investing cash flow	(10.2)	-	-	-
Investing cash flow	(561.5)	(707.1)	(2,510.2)	(608.0)
Free cash flow	(634.4)	(1,707.5)	(19,881.3)	(1,089.0)
Issue of equity / warrants	(7.4)	(7.1)	16,580.8	0.0
Issue/repay debt	1,050.8	1,791.4	4,744.7	2,499.3
Dividends paid	-	-	-	(499.7)
Int Paid	(30.9)	(430.0)	(650.0)	(1,000.0)
Financing cash flow	1,012.5	1,357.0	20,674.0	1,000.3
Beginning cash & cash eq	19.3	397.5	47.8	842.0
Change in cash & cash eq	378.2	(349.6)	794.2	(89.0)
Closing cash & cash eq	397.5	47.8	842.0	753.0

Source: Company, Religare Research

Balance sheet

(Rs mn)	FY06	FY07	FY08E	FY09E
Cash and cash equivalents	397.5	47.8	842.0	753.0
Accounts receivable	773.9	3,102.6	5,100.0	9,024.3
Inventories	4,373.2	11,525.1	21,100.0	35,500.0
Others current assets	1,245.5	2,332.0	23,006.7	30,607.3
Current assets	6,790.1	17,007.5	50,048.7	75,884.6
LT investments	1,132.8	1,650.4	4,100.0	4,654.0
Net fixed assets	49.4	235.9	273.9	308.9
CWIP	10.3	3.5	10.0	10.0
Total assets	7,982.7	18,897.3	54,432.6	80,857.5
Payable	4,081.9	7,218.6	10,071.0	16,861.0
Others	81.6	645.2	3,379.0	5,426.1
Current liabilities	4,163.4	7,863.8	13,450.0	22,287.1
LT debt	1,964.6	3,756.8	8,500.0	11,000.0
Other liabilities	4.4	8.3	18.3	33.3
Equity capital	500.0	1,800.0	2,144.5	2,144.5
Reserves	1,350.1	5,468.3	30,319.7	45,392.7
Networth	1,850.1	7,268.3	32,464.2	47,537.2
Total liabilities	7,982.7	18,897.3	54,432.6	80,857.6
BVPS(Rs)	37.0	40.4	151.4	221.7

Source: Company, Religare Research

Financial ratios

	FY06	FY07	FY08E	FY09E
EBITDA margin(%)	33.2	55.0	58.5	57.9
EBIT margin(%)	33.1	54.9	58.5	57.9
Net profit margin(%)	27.0	45.0	41.5	41.9
EPS growth(%)	-	375.6	33.6	80.8
Receivables(days)	66.9	94.1	89.6	88.6
Tax/PBT	11.8	12.4	25.1	24.1
Payables (days)	-	203.9	187.1	165.1
Current ratio(x)	1.6	2.2	3.7	3.4
Interest coverage(x)	13.3	15.4	18.7	21.5
Debt/equity ratio (x)	1.1	0.5	0.3	0.2
ROE(%)	61.6	74.5	26.5	32.8
ROCE(%)	36.6	60.0	29.7	36.7
ROAE (%)	14.3	28.7	15.8	19.3
EV/Sales(x)	6.3	8.0	5.9	3.4
EV/EBITDA(x)	18.9	14.5	10.0	5.8
P/E (x)	84.3	17.7	13.3	7.3
P/BV (x)	14.4	13.2	3.5	2.4
P/CEPS (x)	23.4	17.7	13.3	7.3

Source: Company, Religare Research

Recommendation tracker

Date	Company	Report type	Stock price (Rs)	Target (Rs)	Reco
30-Jul-07	Apollo Tyres	Results Update	391	498	BUY
30-Jul-07	Federal Bank	Results Update	352	434	BUY
31-Jul-07	RPG Cables	Results Update	48	87	BUY
31-Jul-07	Balaji Telefilms	Results Update	250	317	BUY
01-Aug-07	Nava Bharat Ventures	Results Update	198	302	BUY
01-Aug-07	K S Oils	Results Update	55	68	BUY
01-Aug-07	Bank of Baroda	Results Update	300	343	BUY
01-Aug-07	Dishman Pharmaceuticals and Chemicals	Results Update	315	357	HOLD
01-Aug-07	Cadila	Results Update	351	416	BUY
01-Aug-07	Divi's Laboratories	Results Update	6,692	6,330	HOLD
02-Aug-07	Maruti Udyog	Results Update	821	945	BUY
02-Aug-07	Sangam (India)	Results Update	56	95	BUY
02-Aug-07	KPR Mills	IPO Note	225-265	NA	AVOID
02-Aug-07	Riddhi Siddhi Gluco Biols	Results Update	265	365	BUY
06-Aug-07	Mahindra and Mahindra	Results Update	678	990	BUY
06-Aug-07	Cinemax	Results Update	142	189	BUY
06-Aug-07	Parsvnath Developers	Initiating Coverage	326	512	BUY
08-Aug-07	Wipro Technologies	Company Update	459	595	HOLD
09-Aug-07	Punjab National Bank	Analyst Meet Note	521	610	BUY
13-Aug-07	Bajaj Auto	Company Update	2,319	2,748	BUY
13-Aug-07	IVRCL Infrastructures & Projects	Initiating Coverage	381	488	BUY
13-Aug-07	Inox Leisure	Results Update	121	120	SELL
14-Aug-07	Madhucon Projects	Company Update	247	332	BUY
16-Aug-07	Riddhi Siddhi Gluco Biols	Company Update	270	365	BUY
17-Aug-07	Jindal Drilling and Industries	Initiating Coverage	754	1,056	BUY
20-Aug-07	Motilal Oswal Financial Services	IPO Note	725 – 825	NA	SUBSCRIBE
20-Aug-07	Time Technoplast	Initiating Coverage	525	736	BUY
22-Aug-07	Sujana Towers	Company Update	122	157	BUY
22-Aug-07	Prism Cement	Initiating Coverage	51	81	BUY
24-Aug-07	PVR Cinemas	Company Update	179	277	BUY
27-Aug-07	Cipla	Company Update	171	191	HOLD
27-Aug-07	IT People	FPO Note	40	30-32	NA
28-Aug-07	Ashok Leyland	Company Update	35	48	BUY
29-Aug-07	Parsvnath Developers	Company Update	287	512	BUY
30-Aug-07	Jagran Prakashan	Initiating Coverage	551	662	BUY
30-Aug-07	Deccan Chronicle	Initiating Coverage	228	273	BUY
30-Aug-07	HT Media	Initiating Coverage	211	232	NEUTRAL
03-Sep-07	Central Bank of India	Company Update	125	144	HOLD
04-Sep-07	Maruti Udyog	Company Update	881	945	BUY
05-Sep-07	Parsvnath Developers	Company Update	316	512	BUY
05-Sep-07	MindTree Consulting	Initiating Coverage	589	556	SELL
05-Sep-07	Shri Lakshmi Cotsyn	Initiating Coverage	104	210	BUY
06-Sep-07	Power Grid Corporation of India	IPO Note	44 – 52	NA	SUBSCRIBE
07-Sep-07	Balaji Telefilms	Company Update	255	341	BUY
10-Sep-07	Greenply Industries	Company Update	230	288	BUY
10-Sep-07	HDIL	Initiating Coverage	533	694	BUY
11-Sep-07	Cadila Healthcare	Company Update	320	416	BUY

Market trends

BSE sectoral indices

	% Chg				Constituent performance
	10-Sept	1-day	1-mth	3-mth	
Automobiles	4,900	0.2	3.5	4.2	
Banks	8,100	0.1	4.2	9.1	
Capital Goods	13,654	0.3	6.9	25.7	
Comm. & Tech.	3,605	(1.0)	(1.5)	(3.5)	
Consumer Durables	4,548	1.5	11.2	17.2	
FMCG	2,085	1.9	9.6	16.5	
Healthcare	3,721	0.4	3.3	(0.8)	
IT	4,571	(1.9)	(4.3)	(8.9)	
Metal	11,606	(0.0)	6.8	13.1	
Oil & Gas	8,260	0.9	6.5	11.4	
Mid-caps	6,884	0.5	5.8	12.3	
Small-caps	8,514	1.0	7.7	16.3	

Number of companies: down 5% down 2-5% down 0-2% up 0-2% up 2-5% up 5%

Emerging markets

Country	% Chg				
	10-Sept	1-day	1-mth	3-mth	6-mth
Brazil	52,653	(3.5)	0.0	(0.2)	19.3
Shanghai	5,370	0.3	13.1	34.4	82.8
Hong Kong	24,109	0.5	10.6	16.9	26.0
India	15,597	0.0	4.9	10.7	21.0
South Korea	1,839	0.2	0.6	7.1	29.2
Taiwan	9,016	0.9	0.9	8.1	19.1

FII statistics

(US\$ mn)	1-day	WTD	MTD	YTD
India	142.3	682.0	682.0	9,056.0
South Korea	(214.8)	(214.8)	(329.9)	(14,347.0)
Taiwan	(392.0)	(392.0)	141.3	2,113.4
Thailand	(553.8)	(17.1)	(15.6)	2,951.9

Events calendar

Board meetings

September 10	11	12
	Areva T&D – Results	Asian Oilfie - General Gulshan Poly - General
13	14	15
Adlabs Films – Divident, Results	Orissa Sponge - Results	

Trade data

Institutional bulk deals

Scrip	Client	Buy/Sell	Quantity	Avg Price (Rs)
Alpa Lab	Lotus Global Investments	B	600,000	48.0
Emkay Share	Kotak Mahindra Uk Ac Melchoir Indian Opportunities	B	125,000	146.7
Emkay Share And Stock Bro	Melchoir Indian Opportunities Fund	B	130,000	146.8
Escorts India	Morgan Stanley Dean Witter Mauritius Company	B	504,000	107.7
Helios And Matheson Infor	Grants Investment A/C Fccb	S	138,907	135.5
Kashyap Tec	Lotus Global Investements Account Gdr	S	900,000	6.0
L N Polyeste	Andhra Bank	S	63,640	15.7
Malar Hospit	Chettinad Financial Management Services Priva	B	155,000	32.5
Nagarjuna Fert & Chem	Sundaram Mutual Fund A/C Sundaram Smile Fund	B	2,174,352	43.3
Nagarjuna Fert & Chem	Jaypee Capital Services	S	3,728,969	42.9
Network 18 Fincap	Ruanne Cunniff & Gold Farb Inc	B	460,467	457.0
Network 18 Fincap	Oppenheimer Funds Inc	S	460,467	457.0
Noida Toll Bridge Company	Citi Group Global MktMauritius	B	3,102,385	30.5
Noida Toll Bridge Company	Clsa Merchant Bankers A/C Clsa (Mauritius)	S	3,147,342	30.5
Provogue (India)	Videocon Industries	S	100,000	635.0
Rane Brake Linings	Rane Investments	B	275,000	175.0
Rane Brake Linings	Rane Engine Valves	S	275,000	175.0
Searle (India)	Goldman Sachs Investments Mauritius	S	87,927	108.9
Southbiotec	Mackertich Consultancy Services P	B	160,725	23.7
Vadilal Indu	Ruane Cunniff And Goldfarb Inc Acacia Institutional	B	39,275	71.5
Welspun Gujarat Stahl Roh	Ubs Securities Asia A/C Swiss Finance Cor	S	1,076,480	232.4

Source: BSE

Insider trading

Scrip	Acquirer/Seller	Buy/Sell	Shares transacted		Post-transaction holding	
			Qty	%		
Ambuja Cements	Shri P B Kulkarni	S	3,000	-	1,320,158	0.1
Aptech	Bear Stearns & Co Inc A/C Bsma	S	1,000,000	2.3	1,510,604	3.5
Bajaj Hindustan	Merrill Lynch Cap Mkts Espanan Sa Sv &Pa	B	153,000	0.1	7,322,371	5.2
Bharati Shipyard	Jm Financial Mutual Fund	B	79,536	0.4	1,165,798	-
Choice International	Tenet Bio Pharma	B	5,375	-	1,519,865	39.7
Dabur India	P D Narang	B	25,062	-	1,717,320	0.2
Dabur India	Sunil Duggal	S	2,000	-	1,581,611	0.2
Dabur India	Sunil Duggal	S	2,000	-	1,579,611	0.2
Dabur India	Sunil Duggal	S	3,000	-	1,576,611	0.2
Dabur India	Sunil Duggal	B	18,916	-	1,595,527	0.2
Dabur India	Charanjit Mohan	B	3,339	-	468,512	0.1
Dabur India	Devendra Garg	B	8,902	-	268,756	-
Dabur India	Jude Magima	B	8,902	-	290,334	-
Dabur India	Ambati Sudhakar	B	6,676	-	261,727	-
Dabur India	Rajan Varma	B	6,676	-	252,127	-
Dabur India	A K Jain	B	1,687	-	20,847	-
Deccan Aviation	Brindavan Beverages	S	3,145,680	2.3	4,835,468	3.6
Dolat Investments	Gigantic Investments	S	117,737	0.1	1,082,183	1.2
Gitanjali Gems	Morgan Stanley Mauritius Co & Pac	B	1,000,000	1.7	3,616,617	6.0
Gulshan Sugars & Chemicals	P K Khurana	S	19,326	0.2	1,140,000	8.9
Housing Development Finance CorplT	Girish V Koliyote	S	20	-	-	-
Housing Development Finance CorplT	Girish V Koliyote	S	100	-	-	-
Housing Development Finance CorplT	Girish V Koliyote	S	250	-	1,794	-

Scrip	Acquirer/Seller	Buy/Sell	Shares transacted		Post-transaction holding	
			Qty	%		
Indraprashtha Gas	Hdfc Mid-Cap Opportunities Fund	B	72,000	0.1	3,143,673	2.2
Jsw Steel	Hsbc Global Invt Fund (M) & Pac	B	144,450	0.1	8,258,150	5.0
Kamdhenu Ispat	Kamdhenu Overseas	B	200,000	1.1	1,970,000	-
Liberty Phosphate	Mrs Anisha Raoof Dhanani	B	144,441	2.4	1,500,593	24.5
Lupin	Dr D B Gupta	S	3,350	-	474,146	0.1
Lupin	Dr D B Gupta	S	2,750	-	471,396	0.1
Mahindra Ugine Steel Co	Hemant Luthra	S	4,070	-	11,836	-
Media Video	Rakesh Gupta	B	25,000	0.1	-	-
Omax Autos	Bear Stearns & Co A/C Bsma	S	6,870	-	262,068	1.2
Oricon Enterprises	Sampada Chemicals	S	354,300	3.7	271	-
Oricon Enterprises	S V Trading & Agencies	S	180,000	1.9	264,395	-
Oricon Enterprises	Parijat Shipping & Finale	S	48,400	0.5	33,800	-
Oricon Enterprises	Sarvamangal Mercantile Co	S	100,000	1.0	426,705	-
Oricon Enterprises	Svaraj Trading And Agencies	S	93,000	1.0	305,982	-
Oricon Enterprises	Skybird Trading	S	28,000	0.3	-	-
Oricon Enterprises	Mridula Somani	S	50,000	0.5	250,127	-
Oricon Enterprises	Vandana Somani	S	24,000	0.3	241,465	-
Oricon Enterprises	Varun Somani	S	4,000	-	365,875	-
Oricon Enterprises	Suhrid Somani	S	19,000	0.2	148,205	-
Oricon Enterprises	Shantanu Somani	S	9,500	0.1	174,765	-
Oricon Enterprises	Praveena Virvadia	S	15,000	0.2	--	-
Oricon Enterprises	Renuka Bhansali	S	13,760	0.1	--	-
Oricon Enterprises	Parekh Integrated Services	S	23,040	0.2	250	-
Pitambar Coated Papers	Sumit Apparels	B	706,010	-	706,010	-
Pitambar Coated Papers	Sunil Gupta	B	8,100	0.1	-	-
Pitambar Coated Papers	Subhash Gupta	B	3,100	-	-	-
Pitambar Coated Papers	Sumit Apparels	B	450,000	5.6	1,156,010	8.9
Simplex Projects	Jm Financial Mutual Fund	B	35,070	0.3	622,653	-
Xo Infotech	Naresh Talwar	S	671,810	3.3	-	-
Xo Infotech	Umesh Talwar	S	24,200	-	84,810	0.4
Xo Infotech	Varun Talwar	S	146,715	0.7	-	-
Yash Management & Satellite	Choice International	S	213,750	2.2	336,250	3.5
Zicom Electronic Security Systems L	Goldman Sachs Invt (Mauritius) I	B	838,231	6.6	986,523	7.8

Source: BSE

RELIGARE RESEARCH
Fundamental Research

Amitabh Chakraborty, CFA, FRM	President - Equity	amitabh.chakraborty@religare.in	(91-22) 6612 4603
Piyush Parag	Auto, Auto Ancillaries, Shipping	piyush.parag@religare.in	(91-22) 6612 4730
Abhishek Agarwal	Agri-commodities, Banking	abhishek.a@religare.in	(91-22) 6612 4753
Dinesh Shukla	Agri-commodities, Banking	dinesh.shukla@religare.in	(91-22) 6612 4739
Ram Patnaik	Agri-commodities, Media, FMCG	ram.patnaik@religare.in	(91-22) 6612 4752
Reema Deshkar	Agri-commodities, Media, FMCG	reema.deshkar@religare.in	(91-22) 6612 4764
Vinod Nair	Capital Goods, Engineering, Metals, Media	nair.vinod@religare.in	(91-22) 6612 4731
Ronald Siyoni	Capital Goods, Engineering, Power	ronald.siyoni@religare.in	(91-22) 6612 4615
Dalpat Mehta	Cement, Textiles	dalpat.mehta@religare.in	(91-22) 6612 4696
Anurag Purohit	Information Technology, Telecom	anurag.purohit@religare.in	(91-22) 6612 4795
Hitesh Punjabi	Information Technology, Telecom	hitesh.punjabi@religare.in	(91-22) 6612 4769
Suman Memani	Mid-caps, Construction, Realty	suman.memani@religare.in	(91-22) 6612 4736
Sudeep Anand	Oil & Gas, Chemicals	sudeep.anand@religare.in	(91-22) 6612 4670
Bhawana Verma	Oil & Gas, Chemicals	bhawana.verma@religare.in	(91-22) 6612 4713
Alok Dalal	Pharmaceuticals	alok.dalal@religare.in	(91-22) 6612 4750

Technical Research

Birendrakumar Singh	birendrakumar.singh@religare.in	(91-22) 6612 4657
Vasant Joshi	vasant.joshi@religare.in	(91-22) 6612 4614
Amit Shitut	amit.shitut@religare.in	(91-20) 3024 0376
Kalpana Kabra	kalpana.kabra@religare.in	(91-33) 3051 0947

Derivatives Research

Anil Gupta	anil.g@religare.in	(91-22) 6612 4661
Samir Badami	samir.badami@religare.in	(91-22) 6612 4637
Somendra Agarwal	somendra.agarwal@religare.in	(91-22) 6612 4767

Production

Anisha deSa	anisha.desa@religare.in	(91-22) 6612 4729
R Murali	r.murali@religare.in	(91-22) 6612 4674
Rajesh Mhatre	rajesh.mhatre@religare.in	(91-22) 6612 4728

Administration

Shraddha Hosalkar	shraddha.hosalkar@religare.in	(91-22) 6612 4680
-------------------	-------------------------------	-------------------

Recommendation parameters

			Returns	Absolute
Large-caps*	> 10%	< -5%		
	BUY	SELL		
Mid-caps**	> 25%	< 10%		

*Market cap over US\$ 1bn **Market cap less than US\$ 1bn

Religare Securities

Mumbai: 3rd Floor, Dheeraj Arma, Anant Kanekar Marg, Bandra (East), Mumbai-400 051. Phone: +91 22 66124600 Fax- 66124781

New Delhi: 19, Nehru Place, New Delhi - 110019, Phone: +91 11 30815100.

Disclaimer

Religare Securities Limited (Religare) has two independent equity research groups: Institutional Equities (Institutional Equity Research) and Priority Client Group (Religare Research). Religare Institutional Equity Research is aimed to service the institutional clients of Religare Securities Limited including the Portfolio Management Services of Religare whereas Religare Research is published with a view to service all segments of clients including Retail, HNIs and Institutional clients and PMS.

This document has been prepared by Religare Securities Limited – Priority Client Group. Affiliates of Religare-PCG may have issued other reports that are contrary with and reach different conclusion from the information presented in this report. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating and target price of the Institutional Equities Research Group of Religare Securities Limited.

We are not soliciting any action based upon this material. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Religare-PCG. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Religare-PCG will not treat recipients as customers by virtue of their receiving this report. We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable. It should be noted that the information contained herein is from publicly available data or other sources believed to be reliable. Neither Religare, nor any person connected with it, accepts any liability arising from the use of this document.

This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for any investment decision. The investment discussed or views expressed may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Opinions expressed are our current opinions as of the date appearing on this material only. We do not undertake to advise you as to any change of our views expressed in this document. While we would endeavor to update the information herein on a reasonable basis, Religare, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also there may be regulatory, compliance, or other reasons that may prevent Religare and affiliates from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Religare and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Religare and its affiliates, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall Religare, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Copy right in this document vests exclusively with Religare. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from Religare. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Analyst's holding in the stocks mentioned in the report: **NIL**.